Non-1H nuclei magnetic resonance spectroscopy (MRS) offers insights into metabolism, which may aid for example early stages of disease diagnosis, tissue characterization or therapy response evaluation. Sodium MRI can provide valuable information about tissue health and cellular function. When combined with 31P MR spectroscopic imaging (MRSI), complementary metabolic information on energy metabolism and cell proliferation can be obtained. However, sensitivity challenges stemming from low natural abundances and low gyromagnetic ratios of different nuclei have hindered progress. Besides, due to hardware constraints, different nuclei are often studied separately, and the need for dedicated hardware for x-nuclei imaging hampers clinical efficiency and patient-friendly assessments. This work introduces an interleaved acquisition scheme for 3D 31P-MRSI and 3D radial 23Na-MR imaging (23Na-MRI) at 7 Tesla (7T) and demonstrates the feasibility of interleaving these two nuclei acquisitions. The interleaved protocol effectively merged 31P-MRSI with 23Na-MRI, while remaining within specific absorption rate (SAR) limits. Results revealed comparable signal-to-noise ratios (SNRs) and spectral quality between interleaved and non-interleaved scans, highlighting the approach's efficiency without compromising data quality.
Sodium MRI can provide valuable information about tissue health and cellular function. When combined with 31P MR spectroscopic imaging (MRSI), complementary metabolic information on energy metabolism and cell proliferation can be obtained. This study introduces interleaved 3D 31P‐MRSI and 3D radial 23Na‐MR imaging at 7T, demonstrating the feasibility of interleaving these two nuclei acquisitions. Results confirm similar SNR and spectral quality of data with and without interleaving, affirming this efficient approach without compromising data integrity.
Keywords: 23Na‐MRI; 31P‐MRSI; SAR limits; interleaved x‐nuclei scan; scan efficiency; ultra‐high field.
© 2025 The Author(s). NMR in Biomedicine published by John Wiley & Sons Ltd.